{"entity":{"type":"insider","cik":"0001507220","url":"/insider/0001507220","json_url":"/insider/0001507220.json","name":"Metzger Michael A","name_source":"as-filed","also_issuer":false,"cross_url":null},"coverage_statement":{"n_transactions":48,"n_filings":26,"first":"2012-02-06","last":"2026-07-09","span_basis":"filed_date"},"name_variants":[{"name":"Metzger Michael A","source":"filing","n_filings":26,"first_seen":"2012-02-06","last_seen":"2026-07-09"}],"transactions":[{"id":5873460,"accession":"0001193125-26-299803","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001193125-26-299803","line_url":"/filing/0001193125-26-299803#line-2","is_derivative":false,"issuer_cik":"0001395937","issuer_name":"Syndax Pharmaceuticals Inc","issuer_ticker":"SNDX","issuer_name_source":null,"issuer_url":"/issuer/0001395937","owner_cik":"0001507220","owner_name":"Metzger Michael A","owner_display_name":"Metzger Michael A","owner_url":"/insider/0001507220","role":"Director, Officer (Chief Executive Officer)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Executive Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":32375.0,"shares_display":"32,375","price_per_share":24.2402,"price_display":"24.24","price_state":"stated","total_value":784776.475,"total_display":"784,776.48","total_whole":"784,776","shares_owned_after":484843.0,"shares_owned_after_display":"484,843","ownership_form":"D","is_10b5_1":null,"transaction_date":"2026-07-08","filed_date":"2026-07-09","scope":"insider"},{"id":5896754,"accession":"0001193125-26-253601","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001193125-26-253601","line_url":"/filing/0001193125-26-253601#line-1","is_derivative":false,"issuer_cik":"0001395937","issuer_name":"Syndax Pharmaceuticals Inc","issuer_ticker":"SNDX","issuer_name_source":null,"issuer_url":"/issuer/0001395937","owner_cik":"0001507220","owner_name":"Metzger Michael A","owner_display_name":"Metzger Michael A","owner_url":"/insider/0001507220","role":"Director, Officer (Chief Executive Officer)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Executive Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":6847.0,"shares_display":"6,847","price_per_share":18.99,"price_display":"18.99","price_state":"stated","total_value":130024.53,"total_display":"130,024.53","total_whole":"130,025","shares_owned_after":484843.0,"shares_owned_after_display":"484,843","ownership_form":"D","is_10b5_1":null,"transaction_date":"2026-06-01","filed_date":"2026-06-02","scope":"insider"},{"id":5870249,"accession":"0001193125-26-043814","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001193125-26-043814","line_url":"/filing/0001193125-26-043814#line-1","is_derivative":false,"issuer_cik":"0001395937","issuer_name":"Syndax Pharmaceuticals Inc","issuer_ticker":"SNDX","issuer_name_source":null,"issuer_url":"/issuer/0001395937","owner_cik":"0001507220","owner_name":"Metzger Michael A","owner_display_name":"Metzger Michael A","owner_url":"/insider/0001507220","role":"Director, Officer (Chief Executive Officer)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Executive Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":17159.0,"shares_display":"17,159","price_per_share":21.028,"price_display":"21.03","price_state":"stated","total_value":360819.452,"total_display":"360,819.45","total_whole":"360,819","shares_owned_after":491690.0,"shares_owned_after_display":"491,690","ownership_form":"D","is_10b5_1":null,"transaction_date":"2026-02-09","filed_date":"2026-02-10","scope":"insider"},{"id":6170882,"accession":"0001193125-26-041500","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0001193125-26-041500","line_url":"/filing/0001193125-26-041500#line-3","is_derivative":false,"issuer_cik":"0001395937","issuer_name":"Syndax Pharmaceuticals Inc","issuer_ticker":"SNDX","issuer_name_source":null,"issuer_url":"/issuer/0001395937","owner_cik":"0001507220","owner_name":"Metzger Michael A","owner_display_name":"Metzger Michael A","owner_url":"/insider/0001507220","role":"Director, Officer (Chief Executive Officer)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Executive Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":7412.0,"shares_display":"7,412","price_per_share":20.62,"price_display":"20.62","price_state":"stated","total_value":152835.44,"total_display":"152,835.44","total_whole":"152,835","shares_owned_after":508849.0,"shares_owned_after_display":"508,849","ownership_form":"D","is_10b5_1":null,"transaction_date":"2026-02-06","filed_date":"2026-02-06","scope":"insider"},{"id":5076228,"accession":"0000950170-25-113659","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0000950170-25-113659","line_url":"/filing/0000950170-25-113659#line-2","is_derivative":false,"issuer_cik":"0001395937","issuer_name":"Syndax Pharmaceuticals Inc","issuer_ticker":"SNDX","issuer_name_source":null,"issuer_url":"/issuer/0001395937","owner_cik":"0001507220","owner_name":"Metzger Michael A","owner_display_name":"Metzger Michael A","owner_url":"/insider/0001507220","role":"Director, Officer (Chief Executive Officer)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Executive Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":157307.0,"shares_display":"157,307","price_per_share":16.4139,"price_display":"16.41","price_state":"stated","total_value":2582021.3673,"total_display":"2,582,021.37","total_whole":"2,582,021","shares_owned_after":298661.0,"shares_owned_after_display":"298,661","ownership_form":"D","is_10b5_1":null,"transaction_date":"2025-09-08","filed_date":"2025-09-08","scope":"insider"},{"id":4419055,"accession":"0000950170-25-096947","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0000950170-25-096947","line_url":"/filing/0000950170-25-096947#line-1","is_derivative":false,"issuer_cik":"0001395937","issuer_name":"Syndax Pharmaceuticals Inc","issuer_ticker":"SNDX","issuer_name_source":null,"issuer_url":"/issuer/0001395937","owner_cik":"0001507220","owner_name":"Metzger Michael A","owner_display_name":"Metzger Michael A","owner_url":"/insider/0001507220","role":"Director, Officer (Chief Executive Officer)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Executive Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":7534.0,"shares_display":"7,534","price_per_share":9.285,"price_display":"9.28","price_state":"stated","total_value":69953.19,"total_display":"69,953.19","total_whole":"69,953","shares_owned_after":298661.0,"shares_owned_after_display":"298,661","ownership_form":"D","is_10b5_1":null,"transaction_date":"2025-07-16","filed_date":"2025-07-18","scope":"insider"},{"id":5073992,"accession":"0000950170-25-034634","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0000950170-25-034634","line_url":"/filing/0000950170-25-034634#line-2","is_derivative":false,"issuer_cik":"0001395937","issuer_name":"Syndax Pharmaceuticals Inc","issuer_ticker":"SNDX","issuer_name_source":null,"issuer_url":"/issuer/0001395937","owner_cik":"0001507220","owner_name":"Metzger Michael A","owner_display_name":"Metzger Michael A","owner_url":"/insider/0001507220","role":"Director, Officer (Chief Executive Officer)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Executive Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":7814.0,"shares_display":"7,814","price_per_share":15.0453,"price_display":"15.05","price_state":"stated","total_value":117563.9742,"total_display":"117,563.97","total_whole":"117,564","shares_owned_after":300121.0,"shares_owned_after_display":"300,121","ownership_form":"D","is_10b5_1":null,"transaction_date":"2025-03-04","filed_date":"2025-03-06","scope":"insider"},{"id":4711259,"accession":"0000950170-25-019000","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0000950170-25-019000","line_url":"/filing/0000950170-25-019000#line-1","is_derivative":false,"issuer_cik":"0001395937","issuer_name":"Syndax Pharmaceuticals Inc","issuer_ticker":"SNDX","issuer_name_source":null,"issuer_url":"/issuer/0001395937","owner_cik":"0001507220","owner_name":"Metzger Michael A","owner_display_name":"Metzger Michael A","owner_url":"/insider/0001507220","role":"Director, Officer (Chief Executive Officer)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Executive Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":13288.0,"shares_display":"13,288","price_per_share":15.504,"price_display":"15.50","price_state":"stated","total_value":206017.152,"total_display":"206,017.15","total_whole":"206,017","shares_owned_after":300121.0,"shares_owned_after_display":"300,121","ownership_form":"D","is_10b5_1":null,"transaction_date":"2025-02-10","filed_date":"2025-02-12","scope":"insider"},{"id":8713539,"accession":"0001562180-23-001118","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001562180-23-001118","line_url":"/filing/0001562180-23-001118#line-2","is_derivative":false,"issuer_cik":"0001395937","issuer_name":"Syndax Pharmaceuticals Inc","issuer_ticker":"SNDX","issuer_name_source":null,"issuer_url":"/issuer/0001395937","owner_cik":"0001507220","owner_name":"Metzger Michael A","owner_display_name":"Metzger Michael A","owner_url":"/insider/0001507220","role":"Director, Officer (Chief Executive Officer)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Executive Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":5959.0,"shares_display":"5,959","price_per_share":27.6384,"price_display":"27.64","price_state":"stated","total_value":164697.2256,"total_display":"164,697.23","total_whole":"164,697","shares_owned_after":17659.0,"shares_owned_after_display":"17,659","ownership_form":"D","is_10b5_1":null,"transaction_date":"2023-02-06","filed_date":"2023-02-08","scope":"insider"},{"id":6384674,"accession":"0000891293-22-000055","txn_seq":5,"anchor":"line-5","filing_url":"/filing/0000891293-22-000055","line_url":"/filing/0000891293-22-000055","is_derivative":false,"issuer_cik":"0000891293","issuer_name":"CTI BIOPHARMA CORP","issuer_ticker":"CTIC","issuer_name_source":null,"issuer_url":"/issuer/0000891293","owner_cik":"0001507220","owner_name":"Metzger Michael A","owner_display_name":"Metzger Michael A","owner_url":"/insider/0001507220","role":"Director","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":null,"security_title":"common stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":91500.0,"shares_display":"91,500","price_per_share":5.584905134426229,"price_display":"5.58","price_state":"stated","total_value":511018.8198,"total_display":"511,018.82","total_whole":"511,019","shares_owned_after":41442.0,"shares_owned_after_display":"41,442","ownership_form":"D","is_10b5_1":null,"transaction_date":"2022-11-08","filed_date":"2022-11-10","scope":"insider","n_lines":3},{"id":6822873,"accession":"0001562180-22-007124","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001562180-22-007124","line_url":"/filing/0001562180-22-007124#line-2","is_derivative":false,"issuer_cik":"0001395937","issuer_name":"Syndax Pharmaceuticals Inc","issuer_ticker":"SNDX","issuer_name_source":null,"issuer_url":"/issuer/0001395937","owner_cik":"0001507220","owner_name":"Metzger Michael A","owner_display_name":"Metzger Michael A","owner_url":"/insider/0001507220","role":"Director, Officer (Chief Executive Officer)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Executive Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":16231.0,"shares_display":"16,231","price_per_share":25.2916,"price_display":"25.29","price_state":"stated","total_value":410507.9596,"total_display":"410,507.96","total_whole":"410,508","shares_owned_after":17659.0,"shares_owned_after_display":"17,659","ownership_form":"D","is_10b5_1":null,"transaction_date":"2022-10-06","filed_date":"2022-10-07","scope":"insider"},{"id":6730906,"accession":"0001562180-22-007012","txn_seq":6,"anchor":"line-6","filing_url":"/filing/0001562180-22-007012","line_url":"/filing/0001562180-22-007012#line-6","is_derivative":false,"issuer_cik":"0001395937","issuer_name":"Syndax Pharmaceuticals Inc","issuer_ticker":"SNDX","issuer_name_source":null,"issuer_url":"/issuer/0001395937","owner_cik":"0001507220","owner_name":"Metzger Michael A","owner_display_name":"Metzger Michael A","owner_url":"/insider/0001507220","role":"Director, Officer (Chief Executive Officer)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Executive Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":1280.0,"shares_display":"1,280","price_per_share":25.0206,"price_display":"25.02","price_state":"stated","total_value":32026.368,"total_display":"32,026.37","total_whole":"32,026","shares_owned_after":17659.0,"shares_owned_after_display":"17,659","ownership_form":"D","is_10b5_1":null,"transaction_date":"2022-10-04","filed_date":"2022-10-04","scope":"insider"},{"id":6730899,"accession":"0001562180-22-007012","txn_seq":4,"anchor":"line-4","filing_url":"/filing/0001562180-22-007012","line_url":"/filing/0001562180-22-007012#line-4","is_derivative":false,"issuer_cik":"0001395937","issuer_name":"Syndax Pharmaceuticals Inc","issuer_ticker":"SNDX","issuer_name_source":null,"issuer_url":"/issuer/0001395937","owner_cik":"0001507220","owner_name":"Metzger Michael A","owner_display_name":"Metzger Michael A","owner_url":"/insider/0001507220","role":"Director, Officer (Chief Executive Officer)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Executive Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":2883.0,"shares_display":"2,883","price_per_share":25.011,"price_display":"25.01","price_state":"stated","total_value":72106.713,"total_display":"72,106.71","total_whole":"72,107","shares_owned_after":17659.0,"shares_owned_after_display":"17,659","ownership_form":"D","is_10b5_1":null,"transaction_date":"2022-10-03","filed_date":"2022-10-04","scope":"insider"},{"id":6730891,"accession":"0001562180-22-007012","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001562180-22-007012","line_url":"/filing/0001562180-22-007012#line-2","is_derivative":false,"issuer_cik":"0001395937","issuer_name":"Syndax Pharmaceuticals Inc","issuer_ticker":"SNDX","issuer_name_source":null,"issuer_url":"/issuer/0001395937","owner_cik":"0001507220","owner_name":"Metzger Michael A","owner_display_name":"Metzger Michael A","owner_url":"/insider/0001507220","role":"Director, Officer (Chief Executive Officer)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Executive Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":29606.0,"shares_display":"29,606","price_per_share":25.0205,"price_display":"25.02","price_state":"stated","total_value":740756.923,"total_display":"740,756.92","total_whole":"740,757","shares_owned_after":17659.0,"shares_owned_after_display":"17,659","ownership_form":"D","is_10b5_1":null,"transaction_date":"2022-09-30","filed_date":"2022-10-04","scope":"insider"},{"id":6372130,"accession":"0001562180-22-005761","txn_seq":4,"anchor":"line-4","filing_url":"/filing/0001562180-22-005761","line_url":"/filing/0001562180-22-005761","is_derivative":false,"issuer_cik":"0001395937","issuer_name":"Syndax Pharmaceuticals Inc","issuer_ticker":"SNDX","issuer_name_source":null,"issuer_url":"/issuer/0001395937","owner_cik":"0001507220","owner_name":"Metzger Michael A","owner_display_name":"Metzger Michael A","owner_url":"/insider/0001507220","role":"Director, Officer (Chief Executive Officer)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Executive Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":31602.0,"shares_display":"31,602","price_per_share":21.0554,"price_display":"21.06","price_state":"stated","total_value":665392.7508,"total_display":"665,392.75","total_whole":"665,393","shares_owned_after":17659.0,"shares_owned_after_display":"17,659","ownership_form":"D","is_10b5_1":null,"transaction_date":"2022-07-25","filed_date":"2022-07-27","scope":"insider","n_lines":2},{"id":6822654,"accession":"0001562180-22-005637","txn_seq":4,"anchor":"line-4","filing_url":"/filing/0001562180-22-005637","line_url":"/filing/0001562180-22-005637#line-4","is_derivative":false,"issuer_cik":"0001395937","issuer_name":"Syndax Pharmaceuticals Inc","issuer_ticker":"SNDX","issuer_name_source":null,"issuer_url":"/issuer/0001395937","owner_cik":"0001507220","owner_name":"Metzger Michael A","owner_display_name":"Metzger Michael A","owner_url":"/insider/0001507220","role":"Director, Officer (Chief Executive Officer)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Executive Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":100.0,"shares_display":"100","price_per_share":21.0,"price_display":"21.00","price_state":"stated","total_value":2100.0,"total_display":"2,100.00","total_whole":"2,100","shares_owned_after":17659.0,"shares_owned_after_display":"17,659","ownership_form":"D","is_10b5_1":null,"transaction_date":"2022-07-07","filed_date":"2022-07-08","scope":"insider"},{"id":6713066,"accession":"0000891293-22-000036","txn_seq":6,"anchor":"line-6","filing_url":"/filing/0000891293-22-000036","line_url":"/filing/0000891293-22-000036","is_derivative":false,"issuer_cik":"0000891293","issuer_name":"CTI BIOPHARMA CORP","issuer_ticker":"CTIC","issuer_name_source":null,"issuer_url":"/issuer/0000891293","owner_cik":"0001507220","owner_name":"Metzger Michael A","owner_display_name":"Metzger Michael A","owner_url":"/insider/0001507220","role":"Director","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":null,"security_title":"common stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":20121.0,"shares_display":"20,121","price_per_share":6.51035833209085,"price_display":"6.51","price_state":"stated","total_value":130994.92,"total_display":"130,994.92","total_whole":"130,995","shares_owned_after":11121.0,"shares_owned_after_display":"11,121","ownership_form":"D","is_10b5_1":null,"transaction_date":"2022-07-07","filed_date":"2022-07-11","scope":"insider","n_lines":6},{"id":6822645,"accession":"0001562180-22-005637","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001562180-22-005637","line_url":"/filing/0001562180-22-005637#line-2","is_derivative":false,"issuer_cik":"0001395937","issuer_name":"Syndax Pharmaceuticals Inc","issuer_ticker":"SNDX","issuer_name_source":null,"issuer_url":"/issuer/0001395937","owner_cik":"0001507220","owner_name":"Metzger Michael A","owner_display_name":"Metzger Michael A","owner_url":"/insider/0001507220","role":"Director, Officer (Chief Executive Officer)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Executive Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":15009.0,"shares_display":"15,009","price_per_share":21.0745,"price_display":"21.07","price_state":"stated","total_value":316307.1705,"total_display":"316,307.17","total_whole":"316,307","shares_owned_after":17659.0,"shares_owned_after_display":"17,659","ownership_form":"D","is_10b5_1":null,"transaction_date":"2022-07-06","filed_date":"2022-07-08","scope":"insider"},{"id":6116505,"accession":"0000891293-22-000035","txn_seq":5,"anchor":"line-5","filing_url":"/filing/0000891293-22-000035","line_url":"/filing/0000891293-22-000035","is_derivative":false,"issuer_cik":"0000891293","issuer_name":"CTI BIOPHARMA CORP","issuer_ticker":"CTIC","issuer_name_source":null,"issuer_url":"/issuer/0000891293","owner_cik":"0001507220","owner_name":"Metzger Michael A","owner_display_name":"Metzger Michael A","owner_url":"/insider/0001507220","role":"Director","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":null,"security_title":"common stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":91500.0,"shares_display":"91,500","price_per_share":6.077236698360656,"price_display":"6.08","price_state":"stated","total_value":556067.1579,"total_display":"556,067.16","total_whole":"556,067","shares_owned_after":50958.0,"shares_owned_after_display":"50,958","ownership_form":"D","is_10b5_1":null,"transaction_date":"2022-07-05","filed_date":"2022-07-07","scope":"insider","n_lines":4},{"id":4186549,"accession":"0001562180-21-007809","txn_seq":8,"anchor":"line-8","filing_url":"/filing/0001562180-21-007809","line_url":"/filing/0001562180-21-007809","is_derivative":false,"issuer_cik":"0001395937","issuer_name":"Syndax Pharmaceuticals Inc","issuer_ticker":"SNDX","issuer_name_source":null,"issuer_url":"/issuer/0001395937","owner_cik":"0001507220","owner_name":"Metzger Michael A","owner_display_name":"Metzger Michael A","owner_url":"/insider/0001507220","role":"Director, Officer (President and COO)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"President and COO","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":61000.0,"shares_display":"61,000","price_per_share":20.288,"price_display":"20.29","price_state":"stated","total_value":1237568.0,"total_display":"1,237,568.00","total_whole":"1,237,568","shares_owned_after":17659.0,"shares_owned_after_display":"17,659","ownership_form":"D","is_10b5_1":null,"transaction_date":"2021-12-20","filed_date":"2021-12-20","scope":"insider","n_lines":2},{"id":4186533,"accession":"0001562180-21-007809","txn_seq":4,"anchor":"line-4","filing_url":"/filing/0001562180-21-007809","line_url":"/filing/0001562180-21-007809#line-4","is_derivative":false,"issuer_cik":"0001395937","issuer_name":"Syndax Pharmaceuticals Inc","issuer_ticker":"SNDX","issuer_name_source":null,"issuer_url":"/issuer/0001395937","owner_cik":"0001507220","owner_name":"Metzger Michael A","owner_display_name":"Metzger Michael A","owner_url":"/insider/0001507220","role":"Director, Officer (President and COO)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"President and COO","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":1676.0,"shares_display":"1,676","price_per_share":19.0198,"price_display":"19.02","price_state":"stated","total_value":31877.1848,"total_display":"31,877.18","total_whole":"31,877","shares_owned_after":17659.0,"shares_owned_after_display":"17,659","ownership_form":"D","is_10b5_1":null,"transaction_date":"2021-12-17","filed_date":"2021-12-20","scope":"insider"},{"id":4186525,"accession":"0001562180-21-007809","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001562180-21-007809","line_url":"/filing/0001562180-21-007809#line-2","is_derivative":false,"issuer_cik":"0001395937","issuer_name":"Syndax Pharmaceuticals Inc","issuer_ticker":"SNDX","issuer_name_source":null,"issuer_url":"/issuer/0001395937","owner_cik":"0001507220","owner_name":"Metzger Michael A","owner_display_name":"Metzger Michael A","owner_url":"/insider/0001507220","role":"Director, Officer (President and COO)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"President and COO","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":22715.0,"shares_display":"22,715","price_per_share":19.0799,"price_display":"19.08","price_state":"stated","total_value":433399.9285,"total_display":"433,399.93","total_whole":"433,400","shares_owned_after":17659.0,"shares_owned_after_display":"17,659","ownership_form":"D","is_10b5_1":null,"transaction_date":"2021-12-16","filed_date":"2021-12-20","scope":"insider"},{"id":4383797,"accession":"0001562180-21-007710","txn_seq":4,"anchor":"line-4","filing_url":"/filing/0001562180-21-007710","line_url":"/filing/0001562180-21-007710","is_derivative":false,"issuer_cik":"0001395937","issuer_name":"Syndax Pharmaceuticals Inc","issuer_ticker":"SNDX","issuer_name_source":null,"issuer_url":"/issuer/0001395937","owner_cik":"0001507220","owner_name":"Metzger Michael A","owner_display_name":"Metzger Michael A","owner_url":"/insider/0001507220","role":"Director, Officer (President and COO)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"President and COO","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":36609.0,"shares_display":"36,609","price_per_share":19.0532,"price_display":"19.05","price_state":"stated","total_value":697518.5988,"total_display":"697,518.60","total_whole":"697,519","shares_owned_after":17659.0,"shares_owned_after_display":"17,659","ownership_form":"D","is_10b5_1":null,"transaction_date":"2021-12-13","filed_date":"2021-12-15","scope":"insider","n_lines":2},{"id":5073901,"accession":"0001562180-21-006652","txn_seq":4,"anchor":"line-4","filing_url":"/filing/0001562180-21-006652","line_url":"/filing/0001562180-21-006652#line-4","is_derivative":false,"issuer_cik":"0001395937","issuer_name":"Syndax Pharmaceuticals Inc","issuer_ticker":"SNDX","issuer_name_source":null,"issuer_url":"/issuer/0001395937","owner_cik":"0001507220","owner_name":"Metzger Michael A","owner_display_name":"Metzger Michael A","owner_url":"/insider/0001507220","role":"Director, Officer (President and COO)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"President and COO","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":16296.0,"shares_display":"16,296","price_per_share":19.1964,"price_display":"19.20","price_state":"stated","total_value":312824.5344,"total_display":"312,824.53","total_whole":"312,825","shares_owned_after":17659.0,"shares_owned_after_display":"17,659","ownership_form":"D","is_10b5_1":null,"transaction_date":"2021-10-26","filed_date":"2021-10-27","scope":"insider"},{"id":5073894,"accession":"0001562180-21-006652","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001562180-21-006652","line_url":"/filing/0001562180-21-006652#line-2","is_derivative":false,"issuer_cik":"0001395937","issuer_name":"Syndax Pharmaceuticals Inc","issuer_ticker":"SNDX","issuer_name_source":null,"issuer_url":"/issuer/0001395937","owner_cik":"0001507220","owner_name":"Metzger Michael A","owner_display_name":"Metzger Michael A","owner_url":"/insider/0001507220","role":"Director, Officer (President and COO)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"President and COO","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":44704.0,"shares_display":"44,704","price_per_share":19.1333,"price_display":"19.13","price_state":"stated","total_value":855335.0432,"total_display":"855,335.04","total_whole":"855,335","shares_owned_after":17659.0,"shares_owned_after_display":"17,659","ownership_form":"D","is_10b5_1":null,"transaction_date":"2021-10-25","filed_date":"2021-10-27","scope":"insider"},{"id":5325644,"accession":"0001562180-21-006136","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001562180-21-006136","line_url":"/filing/0001562180-21-006136#line-2","is_derivative":false,"issuer_cik":"0001395937","issuer_name":"Syndax Pharmaceuticals Inc","issuer_ticker":"SNDX","issuer_name_source":null,"issuer_url":"/issuer/0001395937","owner_cik":"0001507220","owner_name":"Metzger Michael A","owner_display_name":"Metzger Michael A","owner_url":"/insider/0001507220","role":"Director, Officer (President and COO)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"President and COO","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":24437.0,"shares_display":"24,437","price_per_share":19.5127,"price_display":"19.51","price_state":"stated","total_value":476831.8499,"total_display":"476,831.85","total_whole":"476,832","shares_owned_after":17659.0,"shares_owned_after_display":"17,659","ownership_form":"D","is_10b5_1":null,"transaction_date":"2021-09-27","filed_date":"2021-09-28","scope":"insider"},{"id":4383522,"accession":"0001562180-21-006060","txn_seq":6,"anchor":"line-6","filing_url":"/filing/0001562180-21-006060","line_url":"/filing/0001562180-21-006060#line-6","is_derivative":false,"issuer_cik":"0001395937","issuer_name":"Syndax Pharmaceuticals Inc","issuer_ticker":"SNDX","issuer_name_source":null,"issuer_url":"/issuer/0001395937","owner_cik":"0001507220","owner_name":"Metzger Michael A","owner_display_name":"Metzger Michael A","owner_url":"/insider/0001507220","role":"Director, Officer (President and COO)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"President and COO","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":300.0,"shares_display":"300","price_per_share":19.02,"price_display":"19.02","price_state":"stated","total_value":5706.0,"total_display":"5,706.00","total_whole":"5,706","shares_owned_after":17659.0,"shares_owned_after_display":"17,659","ownership_form":"D","is_10b5_1":null,"transaction_date":"2021-09-22","filed_date":"2021-09-22","scope":"insider"},{"id":4383515,"accession":"0001562180-21-006060","txn_seq":4,"anchor":"line-4","filing_url":"/filing/0001562180-21-006060","line_url":"/filing/0001562180-21-006060#line-4","is_derivative":false,"issuer_cik":"0001395937","issuer_name":"Syndax Pharmaceuticals Inc","issuer_ticker":"SNDX","issuer_name_source":null,"issuer_url":"/issuer/0001395937","owner_cik":"0001507220","owner_name":"Metzger Michael A","owner_display_name":"Metzger Michael A","owner_url":"/insider/0001507220","role":"Director, Officer (President and COO)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"President and COO","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":4808.0,"shares_display":"4,808","price_per_share":19.1573,"price_display":"19.16","price_state":"stated","total_value":92108.2984,"total_display":"92,108.30","total_whole":"92,108","shares_owned_after":17659.0,"shares_owned_after_display":"17,659","ownership_form":"D","is_10b5_1":null,"transaction_date":"2021-09-21","filed_date":"2021-09-22","scope":"insider"},{"id":4383506,"accession":"0001562180-21-006060","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001562180-21-006060","line_url":"/filing/0001562180-21-006060#line-2","is_derivative":false,"issuer_cik":"0001395937","issuer_name":"Syndax Pharmaceuticals Inc","issuer_ticker":"SNDX","issuer_name_source":null,"issuer_url":"/issuer/0001395937","owner_cik":"0001507220","owner_name":"Metzger Michael A","owner_display_name":"Metzger Michael A","owner_url":"/insider/0001507220","role":"Director, Officer (President and COO)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"President and COO","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":31455.0,"shares_display":"31,455","price_per_share":19.2353,"price_display":"19.24","price_state":"stated","total_value":605046.3615,"total_display":"605,046.36","total_whole":"605,046","shares_owned_after":17659.0,"shares_owned_after_display":"17,659","ownership_form":"D","is_10b5_1":null,"transaction_date":"2021-09-20","filed_date":"2021-09-22","scope":"insider"},{"id":4422719,"accession":"0001562180-21-005948","txn_seq":4,"anchor":"line-4","filing_url":"/filing/0001562180-21-005948","line_url":"/filing/0001562180-21-005948#line-4","is_derivative":false,"issuer_cik":"0001395937","issuer_name":"Syndax Pharmaceuticals Inc","issuer_ticker":"SNDX","issuer_name_source":null,"issuer_url":"/issuer/0001395937","owner_cik":"0001507220","owner_name":"Metzger Michael A","owner_display_name":"Metzger Michael A","owner_url":"/insider/0001507220","role":"Director, Officer (President and COO)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"President and COO","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":44349.0,"shares_display":"44,349","price_per_share":19.1525,"price_display":"19.15","price_state":"stated","total_value":849394.2225,"total_display":"849,394.22","total_whole":"849,394","shares_owned_after":17659.0,"shares_owned_after_display":"17,659","ownership_form":"D","is_10b5_1":null,"transaction_date":"2021-09-14","filed_date":"2021-09-15","scope":"insider"},{"id":4422706,"accession":"0001562180-21-005948","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001562180-21-005948","line_url":"/filing/0001562180-21-005948#line-2","is_derivative":false,"issuer_cik":"0001395937","issuer_name":"Syndax Pharmaceuticals Inc","issuer_ticker":"SNDX","issuer_name_source":null,"issuer_url":"/issuer/0001395937","owner_cik":"0001507220","owner_name":"Metzger Michael A","owner_display_name":"Metzger Michael A","owner_url":"/insider/0001507220","role":"Director, Officer (President and COO)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"President and COO","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":16651.0,"shares_display":"16,651","price_per_share":19.0162,"price_display":"19.02","price_state":"stated","total_value":316638.7462,"total_display":"316,638.75","total_whole":"316,639","shares_owned_after":17659.0,"shares_owned_after_display":"17,659","ownership_form":"D","is_10b5_1":null,"transaction_date":"2021-09-13","filed_date":"2021-09-15","scope":"insider"},{"id":4098060,"accession":"0001562180-21-000869","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001562180-21-000869","line_url":"/filing/0001562180-21-000869#line-2","is_derivative":false,"issuer_cik":"0001395937","issuer_name":"Syndax Pharmaceuticals Inc","issuer_ticker":"SNDX","issuer_name_source":null,"issuer_url":"/issuer/0001395937","owner_cik":"0001507220","owner_name":"Metzger Michael A","owner_display_name":"Metzger Michael A","owner_url":"/insider/0001507220","role":"Director, Officer (President and COO)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"President and COO","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":15000.0,"shares_display":"15,000","price_per_share":20.1866,"price_display":"20.19","price_state":"stated","total_value":302799.0,"total_display":"302,799.00","total_whole":"302,799","shares_owned_after":17659.0,"shares_owned_after_display":"17,659","ownership_form":"D","is_10b5_1":null,"transaction_date":"2021-02-01","filed_date":"2021-02-03","scope":"insider"},{"id":2947495,"accession":"0001562180-20-007070","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001562180-20-007070","line_url":"/filing/0001562180-20-007070#line-2","is_derivative":false,"issuer_cik":"0001395937","issuer_name":"Syndax Pharmaceuticals Inc","issuer_ticker":"SNDX","issuer_name_source":null,"issuer_url":"/issuer/0001395937","owner_cik":"0001507220","owner_name":"Metzger Michael A","owner_display_name":"Metzger Michael A","owner_url":"/insider/0001507220","role":"Director, Officer (President and COO)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"President and COO","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":15000.0,"shares_display":"15,000","price_per_share":22.9675,"price_display":"22.97","price_state":"stated","total_value":344512.5,"total_display":"344,512.50","total_whole":"344,513","shares_owned_after":17659.0,"shares_owned_after_display":"17,659","ownership_form":"D","is_10b5_1":null,"transaction_date":"2020-12-01","filed_date":"2020-12-03","scope":"insider"},{"id":2947387,"accession":"0001562180-20-006583","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001562180-20-006583","line_url":"/filing/0001562180-20-006583#line-2","is_derivative":false,"issuer_cik":"0001395937","issuer_name":"Syndax Pharmaceuticals Inc","issuer_ticker":"SNDX","issuer_name_source":null,"issuer_url":"/issuer/0001395937","owner_cik":"0001507220","owner_name":"Metzger Michael A","owner_display_name":"Metzger Michael A","owner_url":"/insider/0001507220","role":"Director, Officer (President and COO)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"President and COO","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":100000.0,"shares_display":"100,000","price_per_share":20.3141,"price_display":"20.31","price_state":"stated","total_value":2031410.0,"total_display":"2,031,410.00","total_whole":"2,031,410","shares_owned_after":17659.0,"shares_owned_after_display":"17,659","ownership_form":"D","is_10b5_1":null,"transaction_date":"2020-11-04","filed_date":"2020-11-06","scope":"insider"},{"id":2676463,"accession":"0001144204-12-006166","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001144204-12-006166","line_url":"/filing/0001144204-12-006166#line-1","is_derivative":false,"issuer_cik":"0001124608","issuer_name":"RESPONSE GENETICS INC","issuer_ticker":"RGDX","issuer_name_source":null,"issuer_url":"/issuer/0001124608","owner_cik":"0001507220","owner_name":"Metzger Michael A","owner_display_name":"Metzger Michael A","owner_url":"/insider/0001507220","role":"Director","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":null,"security_title":"Common Stock, par value $0.01 per share","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":1000.0,"shares_display":"1,000","price_per_share":1.5,"price_display":"1.50","price_state":"stated","total_value":1500.0,"total_display":"1,500.00","total_whole":"1,500","shares_owned_after":1000.0,"shares_owned_after_display":"1,000","ownership_form":"D","is_10b5_1":null,"transaction_date":"2012-02-02","filed_date":"2012-02-06","scope":"insider"}],"collapsed":true,"next_cursor":null,"ledger_fault":false,"count":{"value":48,"kind":"exact"},"open_market_only":false,"composition":{"kind":"exact","rows":[{"code":"P","label":"Open-market purchase","n":1,"open_market":true},{"code":"S","label":"Open-market sale","n":47,"open_market":true},{"code":"M","label":"Option exercise","n":0,"open_market":false},{"code":"A","label":"Grant or award","n":0,"open_market":false},{"code":"F","label":"Tax withholding","n":0,"open_market":false},{"code":"D","label":"Disposition to the issuer","n":0,"open_market":false},{"code":"X","label":"In-the-money option exercise","n":0,"open_market":false}],"total":48},"affiliations":[{"type":"issuer","type_label":"ISSUER","cik":"0001395937","name":"Syndax Pharmaceuticals Inc","url":"/issuer/0001395937","role":"Director, Officer (Chief Executive Officer)","n_filings":22,"first_seen":"2020-11-06","last_seen":"2026-07-09"},{"type":"issuer","type_label":"ISSUER","cik":"0000891293","name":"CTI BIOPHARMA CORP","url":"/issuer/0000891293","role":"Director","n_filings":3,"first_seen":"2022-07-07","last_seen":"2022-11-10"},{"type":"issuer","type_label":"ISSUER","cik":"0001124608","name":"RESPONSE GENETICS INC","url":"/issuer/0001124608","role":"Director","n_filings":1,"first_seen":"2012-02-06","last_seen":"2012-02-06"}],"order_statement":"Newest transaction date first, id breaking the tie.","canonical_url":"https://ebomi.com/insider/0001507220","retrieved_at":"2026-08-23T20:52:33+00:00","coverage":{"filings":1506293,"transactions":4290787,"issuers":28597,"insiders":152303,"first_filed_date":"2003-06-30","last_filed_date":"2026-08-21","last_ingest":"2026-08-22T05:23:40.159918+00:00","counts_are":{"filings":"estimate","transactions":"estimate","issuers":"estimate","insiders":"estimate"},"source":"SEC EDGAR Form 4 filings, parsed by ebomi","fault":false},"license":{"underlying_records":"US SEC filings are public records of the United States government and are not subject to copyright. The transactional facts in them are not ours to license.","this_presentation":"The parsing, normalisation, curation, and presentation are ebomi's own work.","grant":"undecided","grant_note":"The open licence for ebomi's own layer is an open owner decision (SPEC-20260731T1159Z open question 3: CC BY 4.0 or CC0 with a citation request). Until it is taken, no grant is asserted here.","citation_request":"Balogh, A. Insider trading. Scientific Data 10, 237 (2023)","url":"https://ebomi.com/license"},"fair_use":{"policy":"These JSON endpoints are open and unauthenticated. Please read them at a human pace, identify your client in the User-Agent header, and use the published dataset for bulk work rather than crawling page by page.","bulk_alternative":"doi:10.1038/s41597-023-02147-6"}}